Robert M. Davis's Insider Trades & SAST Disclosures
Robert M. Davis's most recent trade in Merck & Co Inc was a trade of 95,275 Common Stock done at an average price of $97.9 . Disclosure was reported to the exchange on Jan. 27, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert M. Davis.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co Inc | Robert M. Davis | Director, Chairman, CEO & President | Grant, award, or other acquisition of securities at price $ 97.94 per share. | 27 Jan 2025 | 95,275 | 443,601 (0%) | 0% | 97.9 | 9,331,234 | Common Stock |
| Duke Energy Corp. | Robert M. Davis | Director | Grant, award, or other acquisition of securities at price $ 103.06 per share. | 09 May 2024 | 1,698 | 11,053 (0%) | 0% | 103.1 | 175,000 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, Chairman, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 181,641 | 181,641 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Robert Davis M. | Director, Chairman, CEO & President | Sale of securities on an exchange or to another person at price $ 125.74 per share. | 13 Feb 2024 | 124,676 | 373,650 (0%) | 0% | 125.7 | 15,677,147 | Common Stock |
| Merck & Co Inc | M. Davis Robert | Director, Chairman, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 108,491 | 181,781 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Davis Robert M. | Director, Chairman, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 73.73 per share. | 13 Feb 2024 | 108,491 | 498,326 (0%) | 0% | 73.7 | 7,999,041 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, Chairman, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 85,021 | 96,760 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Davis Robert M. | Director, Chairman, CEO & President | Sale of securities on an exchange or to another person at price $ 125.40 per share. | 13 Feb 2024 | 85,021 | 348,326 (0%) | 0% | 125.4 | 10,661,574 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, Chairman, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 73.73 per share. | 13 Feb 2024 | 85,021 | 433,347 (0%) | 0% | 73.7 | 6,268,598 | Common Stock |
| Merck & Co Inc | M. Robert Davis | Director, Chairman, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 41,509 | 83,020 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Robert Davis M. | Director, Chairman, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 75.36 per share. | 13 Feb 2024 | 41,509 | 389,835 (0%) | 0% | 75.4 | 3,128,118 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, Chairman, CEO & President | Sale of securities on an exchange or to another person at price $ 126.37 per share. | 13 Feb 2024 | 25,324 | 348,326 (0%) | 0% | 126.4 | 3,200,277 | Common Stock |
| Merck & Co Inc | M. Davis Robert | Director, Chairman, CEO & President | Grant, award, or other acquisition of securities at price $ 119.43 per share. | 22 Jan 2024 | 76,510 | 348,326 (0%) | 0% | 119.4 | 9,137,589 | Common Stock |
| Duke Energy Corp. | Robert M. Davis | Director | Grant, award, or other acquisition of securities at price $ 98.15 per share. | 04 May 2023 | 1,783 | 9,354 (0%) | 0% | 98.1 | 175,000 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, Chairman, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 186,722 | 186,722 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Robert M. Davis | Director, Chairman, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.04 per share. | 28 Apr 2023 | 143,329 | 415,145 (0%) | 0% | 56.0 | 8,032,157 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, Chairman, CEO & President | Sale of securities on an exchange or to another person at price $ 114.93 per share. | 28 Apr 2023 | 143,329 | 271,816 (0%) | 0% | 114.9 | 16,472,845 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, Chairman, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 143,329 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Robert M. Davis | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 109.88 per share. | 23 Jan 2023 | 24,224 | 271,816 (0%) | 0% | 109.9 | 2,661,733 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2022 | 167,613 | 415,205 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Robert M. Davis | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2022 | 167,613 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Robert M. Davis | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 101.94 per share. | 09 Nov 2022 | 87,595 | 327,610 (0%) | 0% | 101.9 | 8,929,557 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 102.98 per share. | 09 Nov 2022 | 79,918 | 247,692 (0%) | 0% | 103.0 | 8,229,924 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 103.59 per share. | 09 Nov 2022 | 100 | 247,592 (0%) | 0% | 103.6 | 10,359 | Common Stock |
| Duke Energy Corp. | Robert M. Davis | Director | Grant, award, or other acquisition of securities at price $ 110.05 per share. | 05 May 2022 | 1,590 | 7,570 (0%) | 0% | 110.1 | 174,980 | Common Stock |
| Merck & Co Inc | Robert M. Davis | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2022 | 228,155 | 228,155 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Robert M. Davis | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 73.51 per share. | 24 Feb 2022 | 29,896 | 247,592 (0%) | 0% | 73.5 | 2,197,655 | Common Stock |
| Duke Energy Corp. | Robert M. Davis | Director | Grant, award, or other acquisition of securities at price $ 100.57 per share. | 06 May 2021 | 1,591 | 5,980 (0%) | 0% | 100.6 | 160,000 | Common Stock |
| Merck & Co Inc | Robert M. Davis | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2021 | 281,633 | 281,633 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Robert M. Davis | EVP, Global Svcs & CFO | Grant, award, or other acquisition of securities at price $ 72.62 per share. | 26 Feb 2021 | 46,641 | 217,696 (0%) | 0% | 72.6 | 3,387,069 | Common Stock |
| Merck & Co Inc | Robert M. Davis | EVP, Global Svcs & CFO | Sale of securities on an exchange or to another person at price $ 81.03 per share. | 05 Oct 2020 | 251,273 | 171,055 (0%) | 0% | 81.0 | 20,360,325 | Common Stock |
| Merck & Co Inc | Robert M. Davis | EVP, Global Svcs & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 251,273 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Robert M. Davis | EVP, Global Svcs & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 251,273 | 422,328 (0%) | 0% | 0 | Common Stock | |
| Duke Energy Corp. | Robert M. Davis | Director | Grant, award, or other acquisition of securities at price $ 80.32 per share. | 07 May 2020 | 1,992 | 4,388 (0%) | 0% | 80.3 | 160,000 | Common Stock |
| Merck & Co Inc | Robert M. Davis | EVP, Global Svcs & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2020 | 120,823 | 120,823 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges